We have recently shown that von Willebrand factor (vWF) binds to endothelial and fibroblastic extracellular matrixes (ECM) in a dose-dependent, specific, and saturable way. To localize the domain on the vWF subunit responsible for this interaction, purified proteolytic fragments of vWF were compared for their ability to inhibit P latelet adhesion and subsequent thrombus formation at sites of vascular injury are major events of primary hemostasis. The multimeric protein von Willebrand factor (vWF) is essential for platelet adhesion to the subendothelium under flow conditions. Under high-shear-rate conditions, an absolute requirement is established for vWF binding to two distinct platelet glycoprotein (GP) complexes: GPIb-IX, for initial platelet contact with the subendothelium, 1 -3 and GPIIb-IIIa, for platelet spreading and aggregate formation. 4 However, no interaction of vWF with platelets occurs in vitro without their prior activation by the nonphysiological agents ristocetin or botrocetin or by exposure to high shear stress. 5 The in vivo counterpart of this activation is not fully established. A current model is that the binding of circulating plasma vWF to the subendothelium is followed by a conformational change of vWF that allows its interactions with platelets.
I-vWF binding to ECM. A tryptic dimeric fragment of 116 kD (T116), extending from amino acid (aa) residues 449 to 728, produced a significant inhibition of 125 I-vWF binding to the ECM. In contrast, P34 (aa 1-272), Spl (aa 911-1,365), and SpII (aa 1,366-2,050) had no significant effect on 125 I-vWF binding to the ECM. Using an immunoHuorescence technique, we identified type VI collagen and heparan sulfate in the endothelial ECM.
125
I-vWF was found to bind specifically to purified type VI collagen. Unlabeled vWF and Spill were able to completely inhibit 125 I-vWF binding to type VI collagen. T116 and Spl appeared as competitors of this interaction, whereas P34 and SpII were not. Our data suggest that vWF binds to the endothelial ECM through the T116 fragment and that T116 and Spl each contain a binding site for type VI collagen. Heparin is known to be a vWF ligand, but did not appear as a competitor of vWF binding to the ECM, nor did heparan sulfate. (Arteriosclerosis and Thrombosis 1993;13:398-406) KEY WORDS • von Willebrand factor • extracellular matrix • type VI collagen P latelet adhesion and subsequent thrombus formation at sites of vascular injury are major events of primary hemostasis. The multimeric protein von Willebrand factor (vWF) is essential for platelet adhesion to the subendothelium under flow conditions. Under high-shear-rate conditions, an absolute requirement is established for vWF binding to two distinct platelet glycoprotein (GP) complexes: GPIb-IX, for initial platelet contact with the subendothelium, 1 -3 and GPIIb-IIIa, for platelet spreading and aggregate formation. 4 However, no interaction of vWF with platelets occurs in vitro without their prior activation by the nonphysiological agents ristocetin or botrocetin or by exposure to high shear stress. 5 The in vivo counterpart of this activation is not fully established. A current model is that the binding of circulating plasma vWF to the subendothelium is followed by a conformational change of vWF that allows its interactions with platelets. 6 - 7 We and others have demonstrated that platelet adhesion to the subendothelium is not only dependent on circulating plasma vWF but also to a significant extent on the vWF deposited in the subendothelial matrix. 8 - 10 The identification of the subendothelial components that bind to vWF is still a matter of debate. The most likely candidates are collagens and proteoglycans. Studies using purified vWF from plasma have shown that vWF binds to isolated fibrillar collagen types I and III. 1112 Recently, a vWF-binding protein isolated from extracts of vascular subendothelium was found to be type VI collagen, a component of microfibrils that is resistant to collagenase. 13 In addition, binding to solid-phase heparin has been described, 14 but its physiological significance is not established. However, preliminary data were reported on the binding of vWF to heparan sulfate proteoglycan from bovine basement membrane. 15 Limited proteolytic degradation of vWF to dimeric or monomeric fragments has allowed the identification of different binding domains involved in its functions. The GPIb binding site has been identified on two closely connected peptides (amino acid residues [aa] 474-488 and 694-708). 16 Two distinct domains interacting with type I and type HI collagen have been described, one between aa 542-622 and a second domain between aa 948-998. 17 Two binding domains for heparin have also been described, between aa 1-272 18 and between aa 512-673. 1419 Recently, a peptide extending from aa 565 to 587 was identified as a functionally important heparin-binding domain of vWF. 20 We have previously demonstrated that vWF binds to endothelial and fibroblastic extracellular matrix (ECM) in a specific and saturable way. 10 The present work was undertaken to assess in more detail the nature of vWF binding to physiological ligands within the endothelial ECM, a model for the subendothelium. Using purified proteolytic fragments of vWF as competitors for the binding of 125 I-vWF to the ECM, a domain responsible for the interaction of vWF with the ECM was localized on a tryptic fragment, T116, that extends from aa 449 to 728. We also localized two functional domains of vWF involved in its binding to purified type VI collagen, one on T116 and the other one on Spl, a fragment of vWF that extends from aa 911 to 1,365. Finally, we present arguments that heparin or heparan sulfate do not seem to be involved in the vWF-ECM interaction.
Methods

Purification ofvWF and Its Proteolytic Fragments
Human vWF was purified from plasma cryoprecipitates (a gift from CNTS, Paris, and Biotransfusion, Lille, France) by precipitation with 2 M glycine and gel filtration on Sepharose CL4B (Pharmacia Fine Chemicals, Uppsala, Sweden). 21 vWF preparations contained 200 units of vWF antigen per milligram of protein and appeared as one predominant band with a molecular mass of 270 kD by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions. Proteolysis of vWF by Staphylococcus aureus V-8 protease was performed according to the method of Girma et al, 22 which produced three fragments: Spl (monomeric, aa 911-1,365), SpII (dimeric, aa 1,366-2,050), and Spill (dimeric, aa 1-1,365). The monomeric P34 fragment (aa 1-272) 19 was obtained by digestion of purified Spill with plasmin (Boehringer, Meylan, France) as described.
A dimeric 116-kD fragment (T116, aa 449-728) was isolated after trypsin cleavage and heparin-Sepharose chromatography according to Andrews et al. 23 vWF (1 mg/mL) in 0.2 M sodium acetate, pH 7.0, containing 0.02% NaN 3 was digested by 2,500 units trypsin (bovine pancreatic type I, Sigma, La Verpilliere, France) for 2 hours at 37°C. The reaction was terminated with 1 mM diisopropylfluorophosphate (Sigma). The digest was then subjected to affinity chromatography on heparinSepharose CL6B (Pharmacia) equilibrated with 25 mM tris(hydroxymethyl)aminomethane hydrochloride (Tris-HC1), pH 7.4, and 150 mM NaCl (TBS). After extensive washing, T116 was eluted by increasing the salt concentration to 0.5 M. This fragment had an apparent molecular mass of 116 kD under nonreducing conditions and appeared as a doublet of 52/48 kD under reducing conditions as described. 24 Reduction and alkylation of the T116 fragment was performed using dithiothreitol (Boehringer) in equal amounts (wt/wt) and incubation for 1 hour at 37°C. A threefold excess (wt/wt) of iodoacetamide (Sigma) was then added to the mixture and incubated for 30 minutes at 20°C in the dark. The reduced and alkylated sample was extensively dialyzed against TBS at 4°C.
Radiolabeling
vWF, vWF fragments (T116 and Spl), and antibodies were labeled with Na 125 I (Amersham, Les Ulis, France) and Iodo-Gen (Pierce Chemical Co., Rockford, 111.) as described. 10 Specific radioactivity varied from 3 to 10 protein. Labeled proteins were stored at 4°C and used within 4 days for vWF and fragments and 2 months for antibodies.
Binding of 125 I-vWF and m l-Fragments to the Extracellular Matrix
Human umbilical vein endothelial cells were obtained as previously described. 10 At confluence, cells were subcultured (2-3 x 10"/cm 2 ) in microtiter wells (Remova-strips, Dynatech, Marnes-la-Coquette, France) pretreated with 0.05% glutaraldehyde (Merck, Nogentsur-Marne, France) and gelatin (Sigma). ECM was prepared from first-or second-passage cells. Two days after reaching confluence, cell monolayers were exposed to 0.1 M NH 4 OH for 20 minutes followed by extensive washing in 8.8 mM NaH 2 PO 4 , 1.5 mM KH 2 PO 4 , pH 7.4, 137 mM NaCl, and 2.7 mM KC1 (PBS). Binding was assessed in ECM-coated microtiter wells as previously described. 10 Wells were incubated at 20°C for 1 hour with 300 /iL of 25 mM Tris-HCl, pH 7.4, and 100 mM NaCl (binding buffer) containing 2% bovine serum albumin (BSA) and then overnight with 100 /AL 125 I-VWF or 125 I-fragments in binding buffer with 1% BSA. After the incubation period, ECM-coated wells were washed twice with 100 fiL binding buffer and dried. For competition studies, they were incubated with a constant concentration of 
Binding of I25 I-vWF or I25 l-Fragments to Collagen
Type VI collagen was purified by a procedure that includes bacterial collagenase digestion under nonreducing, nondenaturing conditions and gel filtration chromatography. 25 Intact type VI collagen microfibrils from fetal bovine skin were kept in 50 mM Tris-HCl, pH 7.4, containing 400 mM NaCl and protease inhibitors EDTA (10 mM), ./V-ethylmaleimide (2 mM), and phenylmethylsulfonyl fluoride (2 mM). For binding experiments, type VI collagen was dialyzed in 50 mM TrisHCl, pH 7.4, and 100 mM NaCl and incubated overnight in microtiter wells at a concentration of 100 /xg/mL (100 /iL/well). Nonadsorbed collagen was then removed, and the wells were washed twice with binding buffer containing 1% BSA. Wells were incubated for 1 hour with binding buffer containing 2% BSA and for 3 hours with Nonspecific binding was assessed using heat-denatured type III collagen or plastic wells.
In some experiments, collagen-binding assays were performed after preincubating 125 I-vWF with mouse monoclonal antibodies (mAbs) to human vWF prepared in the laboratory and used as purified immunoglobulin G (IgG). 26 Among these, mAb B203 is directed against an epitope localized on Spl and blocks vWF binding to type III collagen. 27 mAb 505 has the same properties, but it does not compete with mAb B203 for binding to vWF and thus is likely to be directed against a distinct epitope on the Spl fragment. We also used mAb 324, which blocks vWF binding to platelet GPIb, 27 and mAb 8, without a known inhibitory effect on vWF functions; these mAbs recognize an epitope on Spill and SpII, respectively.
Indirect Immunofluorescence Studies of Extracellular Matrix
Localization of collagen types I, III, IV, and VI in the ECM was performed by incubation with the following antibodies: polyclonal rabbit anti-human type I, antihuman type III, and goat anti-human type IV collagen antibodies from ERIA Diagnostics, Pasteur, France, purchased as purified IgGs. Rabbit anti-human type VI collagen was from Telios Pharmaceuticals, San Diego, Calif. A rabbit anti-bovine type VI collagen (Ab 5509) that cross-reacts with human type VI collagen was also used as purified IgG. This antibody recognized the intact molecule and the denatured al/a2 chains. The two anti-type VI collagen antibodies were unable to inhibit 125 I-vWF binding to type VI collagen. Identification of heparan sulfate was obtained using a human monoclonal IgM from a patient with Waldenstrom's macroglobulinemia (a kind gift of Dr. J. Arvieux, CTS, Grenoble, France). This antibody is directed against heparan sulfate in a large number of cells, including human endothelial cells from umbilical veins. 28 As controls, sera from patients with monoclonal IgM, devoid of anti-heparan sulfate activity, were used at the same IgM concentration. Endothelial cells were grown on Lab-tek (Miles, France), and ECM was prepared as described. ECM was incubated for 10 minutes with PBS containing 0.1% BSA and for 1 hour with the primary antibody. After washing, the ECM was incubated for 1 hour with the appropriate fluoresceinlabeled antibody (Cappel). Incubations were performed at 20°C except for the anti-heparan sulfate antibody, which was active only at 4°C. 28 Observations were carried out with a photomicroscope (Zeiss, France) equipped for epifluorescence.
Enzymatic Treatment of Extracellular Matrix
ECM-coated microtiter plates were incubated with 0.5 units/mL heparitinase (Sigma) in 50 mM Tris-HCl, pH 7, and 5 mM calcium acetate for 1 hour at 43°C or with 0.5 unit/mL chondroitinase ABC (Miles) in 40 mM Tris-HCl, pH 8, and 60 mM sodium acetate at 37°C.
Results
Identification of the Extracellular Matrix-Binding Domain on the T116 Fragment ofvWF
The localization of the ECM-binding site on the vWF subunit was investigated by estimating the ability of a I-vWF to endothelial ECM was inhibited in a dosedependent way by vWF and its subfragment Spill. At the highest concentrations used, vWF (1.5 nM) and Spill (2.3 /uM) inhibited this binding by 98% and 75%, respectively. Half-maximal inhibition (IC 50 ) was obtained with 30 nM vWF and 150 nM Spill. In contrast, SpII up to 3.6 /xM was not able to significantly inhibit 125 I-vWF binding to matrixes (Figure 1 ). To further localize the vWF domain interacting with the matrixes, three fragments (P34, aa 1-272; T116, aa 449-728; and Spl, aa 911-1,365) with sequences overlapping the Spill fragment were compared for their ability to inhibit 125 I-vWF binding to ECM (Figure 2) . When added at a concentration of 100 n-glmL, unlabeled vWF (0.37 fiM) or Spill (0.6 fiM) inhibited by 85% and 70%, respectively, the binding of 125 I-vWF to the ECM. The inhibitory effect of the dimeric T116 fragment at this concentration (2 ftM) appeared almost complete (90%). In contrast, neither the JV-terminal P34 fragment (2.9 /JLM) nor the central Spl fragment (2 fiM) had any effect on this binding (Figure 2 ). Molar concentrations were calculated after taking into consideration for each case the molecular weight of the constituent subunit, i.e., 270 kD for vWF, 170 kD for Spill, 110 kD for SpII, 34 kD for P34, and 50 kD for Spl, T116, and the 52/48-kD doublet. The effect of the T116 fragment on dent way. However, the inhibitory effect of reduced and alkylated T116 was weaker than that of native T116, since 2 /JM inhibited 125 I-vWF binding by only 50%, whereas at the highest concentration tested (5 ^iM), the inhibition reached 82%. Among the fragments tested, T116 was also the only one able to inhibit 125 I-vWF binding to the ECM produced by human bone marrow fibroblasts, which are devoid of endogenous vWF (not shown).
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In another set of experiments,
125
I-T116 was also tested for its capacity to bind directly to the ECM. Using various concentrations (between 1 and 8 ^ig/mL) of fragment, a low but significant and reproducible specific binding of T116 occurred. Total binding was l±0.1%, and nonspecific binding was 0.3±0.05%. No specific binding of 125 I-SpI was measured on the ECM. Taken together, these data indicate that a vWF domain interacting with ECM is localized on T116, a 116-kD fragment that extends from aa 449 to 728. Since this fragment has been described in purified systems as containing binding sites for several compounds that are present in the ECM, we attempted to identify the vWF ligand in the ECM.
Identification of Type VI Collagen in the Extracellular Matrix
Since type VI collagen has been recently identified as a vWF-binding protein in subendothelial extracts, 13 we investigated its presence in the endothelial ECM. A strongly positive fibrillar staining of endothelial ECM was found by indirect immunofluorescence labeling of ECM with a polyclonal antibody against human type VI collagen (Figure 4) . Distribution of type I and III collagens appeared fibrillar, but type I collagen was more intensely stained than type III (Figure 4 ). Distribution of type IV collagen in the ECM also appeared fibrillar, with a strong positive staining (not shown).
The presence of type VI collagen in the endothelial ECM prompted us to assess in more detail the vWF interaction with purified type VI collagen.
Demonstration of Specific vWF Binding to Purified Type VI Collagen
We developed a quantitative binding assay for 125 IvWF to purified type VI collagen of bovine skin coated onto microtiter wells. We first measured the effect of varying amounts of type VI collagen that were added to the wells ( Figure 5) . A specific binding of 125 I-vWF to type VI collagen was measured that increased with its concentration ( Figure 5 ) and reached 4.2% at the highest collagen concentration tested (320 /ig/mL). Nonspecific binding was always <20% of total binding.
To localize on the vWF subunit the domain responsible for this interaction, unlabeled vWF and its fragments were compared as competitors of 125 I-vWF binding to purified type VI collagen ( Figure 6 ). Unlabeled vWF and Spill were able to completely inhibit 125 I-vWF binding to type VI collagen, and IC50 was obtained in the presence of 10 nM vWF or 70 nM Spill. In contrast, we were unable to demonstrate a significant inhibition in the presence of the complementary SpII fragment, up to the maximal concentration used (1.8 pM) (Figure 6 ). However, a dose-dependent inhibition was seen with T116 and Spl that reached 52% and 40%, respectively, at the highest concentration tested (4 JJM), whereas no effect of
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P34 was observed ( Figure 6 ). For comparison, the Spill subfragments were assessed for their ability to compete with 12? I-vWF binding to type III collagen. Both T116 and Spl (4 /iM) were able to inhibit by - 6 I-Ligand was separated from collagen-associated radioactivity as described in "Methods." For each data point, specific binding was determined, and the percentage of inhibition was determined relative to the specific binding in the absence of competitor. These maximal values were 11 ±0.8% and 3. obtained, but they were significantly higher than the background values: total binding was 0.8±0.1% and 0.6±0.1% for T116 and Spl, respectively, and nonspecific binding was 0.15±0.05% in both cases.
To confirm that Spl is a type VI collagen-binding domain on vWF, we measured the effect on the binding of 125 I-vWF to type VI collagen of two mAbs, B203 and 505, that recognize this fragment and block vWF binding to type III collagen (Table 1) . We obtained about 80% inhibition of vWF binding to type VI collagen with these antibodies (20 /ig/mL), whereas no inhibitory effect was observed in the presence of mAb 324, which blocks vWF binding to GPIb, or mAb 8, which recognizes the SpH fragment. The effect of these mAbs on vWF binding to type HI collagen was similar, with a strong inhibition in the presence of mAbs B203 and 505 and no effect of mAbs 324 and 8.
These results indicate that vWF binding to type III and type VI collagen involves a common site on Spl and that T116 also contains a binding site for type VI collagen.
Identification of Heparan Sulfate as an Extracellular Matrix Component
In addition to the presence of collagen binding sites, T116 is known to contain a heparin-binding site. Therefore, we investigated the presence of heparan sulfate in the endothelial ECM by using indirect immunofluorescence staining. Heparan sulfate was distributed as a strong fibrillar staining in the ECM that was abolished after incubation of the ECM with heparitinase ( Figure  7) . As a control, treatment of the ECM with chondroitinase ABC did not modify the positive staining with the anti-heparan sulfate antibody (not shown).
Absence of Inhibition by Heparin I Heparan Sulfate of the vWF Interaction With the Extracellular Matrix
Finally, we attempted to demonstrate the involvement of the two structurally related glycosaminoglycans, heparin and heparan sulfate, on vWF interaction with the ECM. Enzymatic treatment of the ECM with heparitinase was not effective in releasing a putative vWF ligand, as 125 I-vWF binding to heparitinase-treated ECM was not abolished compared with intact ECM (5% versus 4.8%). In addition, when heparin or heparan sulfate from two different sources (500 /ug/mL) was used as a fluid-phase competitor of 125 I-vWF binding to the ECM, we were unable to demonstrate any significant inhibitory effect. In contrast, only 25 /xg/mL heparin was sufficient to inhibit 50% of 125 I-vWF binding to immobilized heparin, and complete inhibition was obtained at 250 /Ag/mL (D. Baruch et al, unpublished
B FIGURE 7. Photomicrographs showing characterization of heparan sulfate as an extracellular matrix (ECM) component. ECM grown on Lab-Tek was incubated with a human monoclonal immunoglobulin M (IgM) with autoantibody activity against heparan sulfate in the absence (panel A) or presence (panel B) of heparitinase. As a control, ECM was incubated with another human monoclonal IgM that was devoid of activity against heparan sulfate (panel C).
Immunofluorescence staining was performed as described in "Methods." x400. observations). Thus, heparin or heparan sulfate did not appear as a vWF ligand in the ECM.
Discussion
In contrast to the extensive characterization of the interaction between vWF and platelets, 12161922 only a little information is available on the interaction between vWF and the subendothelium. We have previously demonstrated the function of ECM-associated vWF in platelet adhesion and described a specific and saturable binding of vWF to the ECM. 10 The present study demonstrates the localization of an ECM-binding domain on the vWF subunit to a fragment (T116) that extends from aa 449 to 728 and that is already known to contain binding domains for GPIb, heparin, type I or III collagen, and more recently, to sulfatides and botrocetin. fiM) , showing that the native conformation of the protein is not an absolute requirement for its interaction with the ECM. Interestingly, native T116 and the reduced and alkylated 52/48-kD fragment inhibited botrocetin-vWF complex formation in the same way, i.e., with a 10-fold lower IC 50 (-10 nM) for the native fragment than the reduced fragment (-0.1 ^iM). 31 These comparisons suggest that the interactions of the T116 fragment with the ECM and botrocetin may involve similar mechanisms. Botrocetin, a modulator of vWF binding to GPIb in vitro, binds to vWF through three discrete sequences located on the Til6 fragment, between aa 539-643, close to the GPIb-binding site. 31 This interaction allows the complex to bind to GPIb, whereas neither botrocetin nor vWF alone are able to bind to the platelet receptor. In vivo, no binding to GPIb occurs with soluble vWF; in contrast, once vWF is associated to the subendothelium, it is thought that a conformational change takes place, which allows vWF interaction with the platelet receptor. Thus, our results strongly suggest that vWF binding to the ECM through the T116 region involves regulatory elements that may be responsible for a conformational change of vWF and its interaction with the platelets.
In contrast, the C-terminal fragment SpII (aa 1,366-2,050) was not able to interact with the ECM, in apparent contradiction with findings of de Groot et al, 32 who reported that a mAb (CLB-RAg 38) that recognizes an epitope localized in this region of vWF inhibited its binding to the ECM. However, the authors did not directly investigate the ability of a purified fragment recognized by this antibody to interact with the ECM. Thus, this antibody may modulate the binding of vWF to the ECM without binding to the interaction site, as recently reported for the vWF-platelet interaction. 33 Alternatively, we cannot rule out the possibility that the isolated SpII fragment is not in the appropriate conformation to inhibit 125 I-vWF binding to the ECM. Among the components known to bind the T116 fragment, we have identified in the endothelial ECM the presence of heparan sulfate and fibrillar type I and type III collagens, all of which might be relevant for their interaction with vWF. In addition, we have also shown the presence of nonfibrillar type VI collagen, thus confirming the findings of Rand et al 13 on the vascular subendothelium. We then examined whether the present work could help us identify one or more of these compounds as a potential vWF ligand in the ECM.
Heparin and heparan sulfate are negatively charged polysaccharides, with heterogenous compositions and various amounts of 7V-acetyl, N-, and O-sulfate groups on the carbohydrate backbone. These glycosaminoglycans have a close structural similarity but are synthesized by different cells. Heparan sulfate proteoglycans are produced by a large variety of cells, including endothelial cells, whereas heparin is derived from connective tissue-type mast cells. 34 Heparin binding to vWF and T116 was clearly demonstrated to be of an electrostatic nature, 14 but no data are yet available on heparan sulfate binding to vWF. Although we identified the presence of heparan sulfate in the endothelial ECM, two lines of evidence argue against a role for heparan sulfate as a vWF ligand in the ECM. First, neither heparin nor heparan sulfate was able to inhibit vWF binding to ECM. Second, heparitinase treatment of the ECM was not associated with a modification of vWF binding. However, the lack of effect of the glycosaminoglycan side chain does not exclude the possibility that the protein core is able to bind vWF. It remains to be determined whether proteoglycans isolated from endothelial ECM or subendothelium are able to bind vWF. In addition, both native T116 and the reduced 52/48-kD form inhibited vWF binding to heparin with the same IC 50 (2 /JLM), suggesting a different mechanism of binding to the ECM than to heparin. 1924 We next confirmed that fibrillar type I and III collagens were present in the endothelial ECM. Two distinct binding sites of vWF to purified fibrillar collagen type I or III have been reported, T116 and Spl (aa 911-1,365).
-
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' 29 Experiments with purified fragments, a mAb directed specifically against one domain, and recombinant vWF with a deletion in the region of the Til6 fragment have established that these fragments act independently of each other; however, when both sites are present, they appear to interact with each other. 2935 Interestingly, studies with a mAb (mAb CLB-RAg 201) that blocks vWF binding to type I or III collagen via the Spl domain but not its interaction with the ECM suggested that no binding to the ECM could occur through the Spl fragment, and thereby that fibrillar collagens were not involved as a vWF ligand in the ECM.
32
- 36 Our results that the T116 fragment is the only one able to interact with the ECM, whereas both T116 and Spl are involved in the binding to purified fibrillar collagen type I or III, agree with this interpretation. Comparison of the IC 50 's of native Tl 16 and the reduced and alkylated 52/48-kD form on 125 I-vWF interaction with the ECM also suggested a different mechanism of binding to the ECM than to fibrillar collagen, since the interaction with collagen was only inhibited by the native fragment and not by the 52/48-kD fragment.
However, the reduced and alkylated fragment was also shown to be able to inhibit vWF binding to type I collagen, but in that work no data were available on the effect of the unreduced fragment. 37 Type VI collagen is a glycoprotein with a short triple-helical core and large globular domains that is resistant to the effect of bacterial collagenase. 38 Recently, a vWF-binding protein was identified in urea extracts of the subendothelium as type VI collagen. 13 This finding was in agreement with those of Wagner et al, 39 who showed that enzymatic treatment of endothelial ECM with collagenase did not modify vWF distribution while it abolished staining of type IV and V collagen. In this work, we provide evidence that type VI collagen is present in the endothelial ECM. To follow up with the notion that vWF may bind to type VI collagen of the ECM, we obtained bovine skin type VI collagen purified under nondenaturing conditions that retained an intact microfibrillar organization. We were able to demonstrate a specific binding of vWF. In addition, our data show that Spill contains binding sites to type VI collagen, whereas SpII does not. Based on competition studies of 125 I-vWF binding to type VI collagen by Spill subfragments, our results suggest that two vWF fragments, Til6 and Spl, are involved in the binding to purified type VI collagen. As the same proteolytic fragments of vWF that bind to type III collagen are also found to bind to type VI collagen, it is tempting to speculate that vWF binds to the fibrillar part of type VI collagen. The possible involvement of type VI collagen as a vWF ligand in the endothelial ECM opens up a new area of research into the biological role of type VI collagen in the vasculature.
Finally, the demonstration that the sequence extending from aa 449 to 728 within the T116 fragment represents the minimal structure of vWF required for the binding of vWF to the ECM appears to be of considerable interest, in keeping with recently published data on the regulatory mechanism involved in the binding of vWF to GPIb. This region on the vWF subunit appears to contain all the reported mutations or insertions in patients with type IIB von Willebrand disease, 40 -43 which is characterized by an increased affinity of vWF for GPIb. 44 Investigation of the ability of vWF from these patients or of recombinant mutant vWF to bind to the ECM could help elucidate the molecular mechanisms of their abnormal interaction with platelets.
